Emerging growth opportunities in the next-generation immune checkpoint inhibitors market include the development of therapies targeting novel immune pathways employed to tackle cancer resistance ...
CTX-8371, a novel dual checkpoint blocker that simultaneously targets the programmed death receptor PD-1 and its ligand PD-L1, demonstrated promising monotherapy clinical activity in patients with ...
The acquisition will be for an upfront cash payment of 4.10 dollars per share, aggregating up to 355 million dollars, the Sun ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results